These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17428320)

  • 21. The genetic epidemiology of breast cancer genes.
    Thompson D; Easton D
    J Mammary Gland Biol Neoplasia; 2004 Jul; 9(3):221-36. PubMed ID: 15557796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic variants associated with breast-cancer risk.
    Narod SA
    Lancet Oncol; 2011 May; 12(5):415-6. PubMed ID: 21514220
    [No Abstract]   [Full Text] [Related]  

  • 23. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations.
    Broeks A; Russell NS; Floore AN; Urbanus JH; Dahler EC; van T Veer MB; Hagenbeek A; Noordijk EM; Crommelin MA; van Leeuwen FE; van T Veer LJ
    Int J Radiat Biol; 2000 May; 76(5):693-8. PubMed ID: 10866292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.
    Concannon P; Haile RW; Børresen-Dale AL; Rosenstein BS; Gatti RA; Teraoka SN; Diep TA; Jansen L; Atencio DP; Langholz B; Capanu M; Liang X; Begg CB; Thomas DC; Bernstein L; Olsen JH; Malone KE; Lynch CF; Anton-Culver H; Bernstein JL;
    Cancer Res; 2008 Aug; 68(16):6486-91. PubMed ID: 18701470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
    Kontorovich T; Cohen Y; Nir U; Friedman E
    Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy in the treatment of hereditary breast cancer.
    Pierce LJ; Haffty BG
    Semin Radiat Oncol; 2011 Jan; 21(1):43-50. PubMed ID: 21134653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
    Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
    Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
    Kleibl Z; Kristensen VN
    Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
    Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
    Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare variants in the ATM gene and risk of breast cancer.
    Goldgar DE; Healey S; Dowty JG; Da Silva L; Chen X; Spurdle AB; Terry MB; Daly MJ; Buys SM; Southey MC; Andrulis I; John EM; ; ; Khanna KK; Hopper JL; Oefner PJ; Lakhani S; Chenevix-Trench G
    Breast Cancer Res; 2011 Jul; 13(4):R73. PubMed ID: 21787400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
    Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
    Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic predisposition to breast cancer: past, present, and future.
    Turnbull C; Rahman N
    Annu Rev Genomics Hum Genet; 2008; 9():321-45. PubMed ID: 18544032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
    Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
    Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations.
    McDuff SGR; Bellon JR; Shannon KM; Gadd MA; Dunn S; Rosenstein BS; Ho AY
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1373-1382. PubMed ID: 33545302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.
    Broeks A; Urbanus JH; Floore AN; Dahler EC; Klijn JG; Rutgers EJ; Devilee P; Russell NS; van Leeuwen FE; van 't Veer LJ
    Am J Hum Genet; 2000 Feb; 66(2):494-500. PubMed ID: 10677309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.